Skip to main content
Premium Trial:

Request an Annual Quote

BioSkryb: Gary Harton

BioSkryb, a Durham, North Carolina-based developer of genomic amplification technologies, has appointed Gary Harton as CSO. Harton has more than 30 years of experience in single-cell diagnostic product development, and will apply BioSkryb’s platform technology to develop new diagnostic technologies for cancer, neurological disorders, and assisted reproductive technologies, the company said. Prior to BioSkryb, he was the portfolio director for preimplantation genetic testing at PerkinElmer. He has also previously held a variety of product and portfolio-development positions at PerkinElmer, Igenomix US, Progyny, Illumina, BlueGnome, and Reprogenetics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.